Literature DB >> 18178815

ICOS controls the pool size of effector-memory and regulatory T cells.

Yvonne Burmeister1, Timo Lischke, Anja C Dahler, Hans Werner Mages, Kong-Peng Lam, Anthony J Coyle, Richard A Kroczek, Andreas Hutloff.   

Abstract

ICOS is an important regulator of T cell effector function. ICOS-deficient patients as well as knockout mice show severe defects in T cell-dependent B cell responses. Several in vitro and in vivo studies attributed this phenomenon to impaired up-regulation of cell surface communication molecules and cytokine synthesis by ICOS-deficient T cells. However, we now could show with Ag-specific T cells in a murine adoptive transfer system that signaling via ICOS does not significantly affect early T cell activation. Instead, ICOS substantially contributes to the survival and expansion of effector T cells upon local challenge with Ag and adjuvant. Importantly, the observed biological function of ICOS also extends to FoxP3+ regulatory T cells, as can be observed after systemic Ag delivery without adjuvant. In line with these findings, absence of ICOS under homeostatic conditions of nonimmunized mice leads to a reduced number of both effector-memory and FoxP3+ regulatory T cells. Based on these results, we propose a biological role for ICOS as a costimulatory, agonistic molecule for a variety of effector T cells with differing and partly opposing functional roles. This concept may reconcile a number of past in vivo studies with seemingly contradictory results on ICOS function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178815     DOI: 10.4049/jimmunol.180.2.774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  95 in total

Review 1.  Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

Review 2.  Follicular helper T cells in immunity and systemic autoimmunity.

Authors:  Joseph E Craft
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

Review 3.  T cells that promote B-Cell maturation in systemic autoimmunity.

Authors:  Jason S Weinstein; Sairy G Hernandez; Joe Craft
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

Review 4.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

5.  CagA-dependent downregulation of B7-H2 expression on gastric mucosa and inhibition of Th17 responses during Helicobacter pylori infection.

Authors:  Taslima T Lina; Irina V Pinchuk; Jennifer House; Yoshio Yamaoka; David Y Graham; Ellen J Beswick; Victor E Reyes
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

Review 6.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

7.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

Authors:  Jose R Cortes; Alberto Ambesi-Impiombato; Lucile Couronné; S Aidan Quinn; Christine S Kim; Ana C da Silva Almeida; Zachary West; Laura Belver; Marta Sanchez Martin; Laurianne Scourzic; Govind Bhagat; Olivier A Bernard; Adolfo A Ferrando; Teresa Palomero
Journal:  Cancer Cell       Date:  2018-02-02       Impact factor: 31.743

8.  ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity.

Authors:  Hadi Maazi; Nisheel Patel; Ishwarya Sankaranarayanan; Yuzo Suzuki; Diamanda Rigas; Pejman Soroosh; Gordon J Freeman; Arlene H Sharpe; Omid Akbari
Journal:  Immunity       Date:  2015-03-10       Impact factor: 31.745

9.  ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis.

Authors:  Georgina Galicia; Ahmad Kasran; Catherine Uyttenhove; Kathleen De Swert; Jacques Van Snick; Jan L Ceuppens
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

10.  CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Authors:  Chrysoula I Liakou; Ashish Kamat; Derek Ng Tang; Hong Chen; Jingjing Sun; Patricia Troncoso; Christopher Logothetis; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.